Buprenorphine for opioid dependence

References

• Walsh SL, Preston KL, Stitzer ML, Cone EJ, Bigelow GE. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin. Pharmacol. Ther.55(5), 569–580 (1994).
   PubMed Web of Science ®Google Scholar
• Amass L, Ling W, Freese TE et al. Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience. Am. J. Addict.13(Suppl. 1), S42–S66 (2004).
   PubMed Web of Science ®Google Scholar
• Ling W, Amass L, Shoptaw S et al. A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network. Addiction100(8), 1090–1100 (2005).
   PubMed Web of Science ®Google Scholar
• Ling W, Wesson DR, Charuvastra C, Klett CJ. A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Arch. Gen. Psychiatry53(5), 401–407 (1996).
   PubMed Web of Science ®Google Scholar
• Schuh KJ, Johanson CE. Pharmacokinetic comparison of the buprenorphine sublingual liquid and tablet. Drug Alcohol Depend.56(1), 55–60 (1999).
   PubMed Web of Science ®Google Scholar
• Chiang CN, Hawks RL. Pharmacokinetics of the combination tablet of buprenorphine and naloxone. Drug Alcohol Depend.70(2 Suppl.), S39–S47 (2003).
   PubMed Web of Science ®Google Scholar
• Compton P, Ling W, Moody D, Chiang N. Pharmacokinetics, bioavailability and opioid effects of liquid versus tablet buprenorphine. Drug Alcohol Depend.82(1), 25–31 (2006).
   PubMed Web of Science ®Google Scholar
• Compton P, Ling W, Chiang N, Moody DE, Huber A, Charuvastra C. Pharmacokinetics of buprenorphine: a comparison of sublingual tablet versus liquid after chronic dosing. J. Addict. Med.1, 88–95 (2007).
   PubMed Web of Science ®Google Scholar
• Harris DS, Jones RT, Welm S, Upton RA, Lin E, Mendelson J. Buprenorphine and naloxone co-administration in opiate-dependent patients stabilized on sublingual buprenorphine. Drug Alcohol Depend.61(1), 85–94 (2000).
   PubMed Web of Science ®Google Scholar
• Hitzemann R, Chiang CN, Cerveny P et al. Buprenorphine-naloxone (4:1) combination – dose proportionality after sublingual administration (Abstract). Presented at: Proceedings of the 60th Annual Scientific Meeting of the College on Problems fo Drug Dependence. Scottsdale, AZ, USA 13–18 June 1998.
   Google Scholar
• Jones ET, Mendelson J, Upton R. An open-label, partially blinded, balanced 4 × 4 latin square crossover study to evaluate the pharmacokinetic and dose-proportionality of buprenorphine when administered in sublingual tablets alone or in combination with naloxone in nondependent opiate users. NIDA Contract N01DA-4–8306 Report, Pharmacokinetic and Pharmacodynamic Studies for Medication Development (1997).
   Google Scholar
• Ciraulo DA, Hitzemann RJ, Somoza E et al. Pharmacokinetics and pharmacodynamics of multiple sublingual buprenorphine tablets in dose-escalation trials. J. Clin. Pharmacol.46(2), 179–192 (2006).
   PubMed Web of Science ®Google Scholar
• Jones RT, Mendelson J. Determination of buprenorphine mass balance. NIDA Contract N01DA-4–8306 Report, Pharmacokinetic and Pharmacodynamic Studies for Medication Development (1997).
   Google Scholar
• Amass L, Bickel WK, Higgins ST, Hughes JR. A preliminary investigation of outcome following gradual or rapid buprenorphine detoxification. J. Addict. Dis.13(3), 33–45 (1994).
   PubMed Web of Science ®Google Scholar
• Woody GE, Poole SA, Subramaniam G et al. Extended vs short-term buprenorphine–naloxone for treatment of opioid-addicted youth: a randomized trial. JAMA300(17), 2003–2011 (2008).
   PubMed Web of Science ®Google Scholar
• Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst. Rev.2, CD002207 (2008).
   PubMed Web of Science ®Google Scholar
• Ling W, Hillhouse M, Domier C et al. Buprenorphine tapering schedule and illicit opioid use. Addiction104(2), 256–265 (2009).
   PubMed Web of Science ®Google Scholar
• Rosado J, Walsh SL, Bigelow GE, Strain EC. Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadone. Drug Alcohol Depend.90(2–3), 261–269 (2007).
   PubMed Web of Science ®Google Scholar
• Jasinski DR, Pevnick JS, Griffith JD. Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction. Arch. Gen. Psychiatry35(4), 501–516 (1978).
   PubMed Web of Science ®Google Scholar
• Johnson RE, Eissenberg T, Stitzer ML, Strain EC, Liebson IA, Bigelow GE. A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence. Drug Alcohol Depend.40(1), 17–25 (1995).
   PubMed Web of Science ®Google Scholar
• Ling W, Charuvastra C, Collins JF et al. Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. Addiction93(4), 475–486 (1998).
   PubMed Web of Science ®Google Scholar
• Mello NK, Mendelson JH. Buprenorphine suppresses heroin use by heroin addicts. Science207(4431), 657–659 (1980).
   PubMed Web of Science ®Google Scholar
• Mello NK, Bree MP, Mendelson JH. Comparison of buprenorphine and methadone effects on opiate self-administration in primates. J. Pharmacol. Exp. Ther.225(2), 378–386 (1983).
   PubMed Web of Science ®Google Scholar
• Amass L, Kamien JB, Branstetter SA, Mikulich SK. A controlled comparison of the buprenorphine–naloxone tablet and methadone for opioid maintenance treatment: interim results. In: Problems of Drug Dependence NIDA Research Monograph Series, No. 180. NIH Publication No. 00-4737. Harris LS (Ed.). US Government Printing Office, Washington DC, USA 161 (2000).
   Google Scholar
• O’Connor PG, Oliveto AH, Shi JM et al. A randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic. Am. J. Med.105(2), 100–105 (1998).
   PubMed Web of Science ®Google Scholar
• Bickel WK, Stitzer ML, Bigelow GE, Liebson IA, Jasinski DR, Johnson RE. A clinical trial of buprenorphine: comparison with methadone in the detoxification of heroin addicts. Clin. Pharmacol. Ther.43(1), 72–78 (1988).
   PubMed Web of Science ®Google Scholar
• Raisch DW, Fye CL, Boardman KD, Sather MR. Opioid dependence treatment, including buprenorphine/naloxone. Ann. Pharmacother.36(2), 312–321 (2002).
   PubMed Web of Science ®Google Scholar
• Chawarski MC, Schottenfeld RS, O’Connor PG, Pakes J. Plasma concentrations of buprenorphine 24 to 72 hours after dosing. Drug Alcohol Depend.55(1–2), 157–163 (1999).
   PubMed Web of Science ®Google Scholar
• Pickworth WB, Johnson RE, Holicky BA, Cone EJ. Subjective and physiologic effects of intravenous buprenorphine in humans. Clin. Pharmacol. Ther.53(5), 570–576 (1993).
   PubMed Web of Science ®Google Scholar
• Chiang CN, Hawks R. Development of a buprenorphine–naloxone combination drug for the treatment of drug addiction. In: Problems of Drug Dependence NIDA Research Monograph Series, No. 141. Harris LS (Ed.). National Institute on Drug Abuse, MD, USA 458 (1994).
   Google Scholar
• Nath RP, Upton RA, Everhart ET et al. Buprenorphine pharmacokinetics: relative bioavailability of sublingual tablet and liquid formulations. J. Clin. Pharmacol.39(6), 619–623 (1999).
   PubMed Web of Science ®Google Scholar
• Preston KL, Bigelow GE, Liebson IA. Buprenorphine and naloxone alone and in combination in opioid-dependent humans. Psychopharmacology (Berl.)94(4), 484–490 (1988).
   PubMed Web of Science ®Google Scholar
• Stoller KB, Bigelow GE, Walsh SL, Strain EC. Effects of buprenorphine/naloxone in opioid-dependent humans. Psychopharmacology (Berl.)154(3), 230–242 (2001).
   PubMed Web of Science ®Google Scholar
• Strain EC, Stoller K, Walsh SL, Bigelow GE. Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers. Psychopharmacology (Berl.)148(4), 374–383 (2000).
   PubMed Web of Science ®Google Scholar
• Mendelson J, Jones RT, Welm S et al. Buprenorphine and naloxone combinations: the effects of three dose ratios in morphine-stabilized, opiate-dependent volunteers. Psychopharmacology (Berl.)141(1), 37–46 (1999).
   PubMed Web of Science ®Google Scholar
• Auriacombe M, Fatséas M, Dubernet J, Daulouède JP, Tignol J. French field experience with buprenorphine. Am. J. Addict.13(Suppl. 1), S17–S28 (2004).
   PubMed Web of Science ®Google Scholar
• Kakko J, Svanborg KD, Kreek MJ, Heilig M. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. Lancet361(9358), 662–668 (2003).
   PubMed Web of Science ®Google Scholar
• Petitjean S, Stohler R, Déglon JJ et al. Double-blind randomized trial of buprenorphine and methadone in opiate dependence. Drug Alcohol Depend.62(1), 97–104 (2001).
   PubMed Web of Science ®Google Scholar
• Lintzeris N, Ritter A, Dunlop A, Muhleisen P. Training primary health care professionals to provide buprenorphine and LAAM treatment. Subst. Abus.23(4), 245–254 (2002).
   PubMedGoogle Scholar
• O’Connor PG. Treating opioid dependence – new data and new opportunities. N. Engl. J. Med.343(18), 1332–1334 (2000).
   PubMed Web of Science ®Google Scholar
• Fiellin DA, Rosenheck RA, Kosten TR. Office-based treatment for opioid dependence: reaching new patient populations. Am. J. Psychiatry158(8), 1200–1204 (2001).
   PubMed Web of Science ®Google Scholar
• Bridge TP, Fudala PJ, Herbert S, Leiderman DB. Safety and health policy considerations related to the use of buprenorphine/naloxone as an office-based treatment for opiate dependence. Drug Alcohol Depend.70(2 Suppl.), S79–S85 (2003).
   PubMed Web of Science ®Google Scholar
• Leshner AI. Accessing opiate dependence treatment medications: buprenorphine products in an office-based setting. Drug Alcohol Depend.70(2 Suppl.), S103–S104 (2003).
   Google Scholar
• Fudala PJ, Bridge TP, Herbert S et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N. Engl. J. Med.349(10), 949–958 (2003).
   PubMed Web of Science ®Google Scholar
• Cicero TJ, Surratt HL, Inciardi J. Use and misuse of buprenorphine in the management of opioid addiction. J. Opioid Manag.3(6), 302–308 (2007).
   PubMedGoogle Scholar
• Bogenschutz M, Kushner R, Tonigan J, Woody G. Effects of buprenorphine and hepatitis C on liver enzymes in adolescents and young adults. Poster presented at: The College on Problems of Drug Dependence (CPDD) Annual Meeting San Juan, Puerto Rico, 14–19 June 2008.
   Google Scholar
• Wedam EF, Bigelow GE, Johnson RE, Nuzzo PA, Haigney MC. QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. Arch. Intern. Med.167(22), 2469–2475 (2007).
   PubMed Web of Science ®Google Scholar
• Jaffe JH, O’Keeffe CO. From morphine clinics to buprenorphine: regulating opioid agonist treatment of addiction in the United States. Drug Alcohol Depend.70(2 Suppl.), S3–S11 (2003).
   PubMed Web of Science ®Google Scholar
• Ling W, Smith D. Buprenorphine: blending practice and research. J. Subst. Abuse Treat.23(2), 87–92 (2002).
   PubMed Web of Science ®Google Scholar